Structures of Receptor Complexes of a North American H7N2 Influenza Hemagglutinin with a Loop Deletion in the Receptor Binding Site

Hua Yang, Li-Mei Chen, Paul J. Carney, Ruben O. Donis, James Stevens*

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Abstract

Human infections with subtype H7 avian influenza viruses have been reported as early as 1979. In 1996, a genetically stable 24-nucleotide deletion emerged in North American H7 influenza virus hemagglutinins, resulting in an eight amino acid deletion in the receptor-binding site. The continuous circulation of these viruses in live bird markets, as well as its documented ability to infect humans, raises the question of how these viruses achieve structural stability and functionality. Here we report a detailed molecular analysis of the receptor binding site of the North American lineage subtype H7N2 virus A/New York/107/2003 (NY107), including complexes with an avian receptor analog (3′-sialyl-N-acetyllactosamine, 3′SLN) and two human receptor analogs (6′-sialyl-N-acetyllactosamine, 6′SLN; sialylacto-N-tetraose b, LSTb). Structural results suggest a novel mechanism by which residues Arg220 and Arg229 (H3 numbering) are used to compensate for the deletion of the 220-loop and form interactions with the receptor analogs. Glycan microarray results reveal that NY107 maintains an avian-type (α2-3) receptor binding profile, with only moderate binding to human-type (α2-6) receptor. Thus despite its dramatically altered receptor binding site, this HA maintains functionality and confirms a need for continued influenza virus surveillance of avian and other animal reservoirs to define their zoonotic potential.

Introduction

Influenza is an acute respiratory virus that infects up to 20% of the population in the United States, resulting in ~36,000 deaths annually [1,2]. The two membrane glycoproteins on the surface of influenza A virus, hemagglutinin (HA), which functions as the receptor binding and membrane fusion glycoprotein in cell entry, and neuraminidase (NA), which functions as the receptor destroying enzyme in virus release, form the basis for defining subtypes [3]. To date, 16 HA (H1–H16) and 9 NA (N1–N9) have been identified in avian species [4], while in the last century, only three subtypes, H1N1 in 1918 and 2009, H2N2 in 1957, and H3N2 in 1968 [5,6,7], have successfully adapted to humans. Hemagglutinin binds to sialic acid (SA) glycans present on host cell surfaces. The receptors on epithelial cells of the human upper respiratory tract are mainly α2-6-linked SA moieties [8]. Since avian influenza viruses predominantly bind α2-3-linked SA, and human influenza viruses preferentially bind to α2-6-linked SA, human infection by avian influenza viruses is rare [9]. However, since 1997 a growing number of human cases of avian influenza infection have been reported [10], including H5N1, H7N2, H7N3, H7N7, and H9N2 strains [11]. Although the current situation with the pandemic H1N1 influenza virus dominates public health efforts, the prospect of a novel pandemic emerging from these isolated cases continues to be a major public health threat around the world.

Early cases of human infection by H7 influenza viruses are reported as far back as 1979 [12,13]. Since 2002, multiple outbreaks and human infections of H7 subtype viruses; within both Eurasian and North American lineages have been reported. In the Netherlands in 2003, a highly pathogenic avian influenza (HPAI) H7N7 outbreak resulted in more than 80 cases of human infections, including one fatality [14,15]. In New York in 2003, a single case of human respiratory infection of H7N2 was reported [16] and in British Columbia in 2004, an H7N3 virus caused two cases of conjunctivitis [17,18]. More recently in 2007, the United Kingdom reported several cases of low pathogenic avian influenza (LPAI) H7N2 virus infections that caused influenza-like illness and conjunctivitis [19]. Since 1996, H7 viruses of the North American lineage have been circulating in regional live bird markets [20], containing a 24-nucleotide deletion resulting in an eight amino acid deletion in the receptor-binding site (RBS) of HA (Figure S1). The recent human infections with H7 in North America have raised public health concerns as to how these viruses adapt to such a dramatic structural change while remaining one of the predominant circulating viral strains. A recent study of H7 viruses isolated from previous outbreaks revealed efficient replication in both mouse and ferret animal models [21]. In particular, ferret studies with A/New York/107/2003 (NY107), an H7N2 virus isolated from a man in New York, not only showed efficient replication in the upper respiratory tract of the ferret but also the capacity for...
Overall structure

By using x-ray crystallography, the structure of H7 HA from the NY107 virus was determined to 2.6 Å resolution (Table 1). In addition, we also report three H7 HA receptor complex structures, with avian receptor analog (3'SLN) to 2.7 Å resolution and with human receptor analogs (6'SLN and LSTb) to 3.0 Å and 2.6 Å resolution, respectively (Table 1). The overall structure of NY107 is similar to other reported HA structures with a globular head containing the RBS and vestigial esterase domain, and a membrane proximal domain with its distinctive, central helical stalk and HA1/HA2 cleavage site (Figure 1A). Although five asparagine-linked glycosylation sites are predicted in the NY107 HA monomer, interpretable electron density was observed at only two sites, Asn38 in HA1 and Asn82 in HA2 (all residue numbers are based on H3 numbering). At these sites, only one or two N-acetyl glucosamines could be interpreted.

During viral replication, HA is synthesized as a single chain precursor (HA0) and cleaved by specific host proteases into the infectious HA1/HA2 form. In baculovirus expression systems, highly pathogenic HAs, with a polybasic cleavage site, are expressed as an HA1/HA2 form [24], whereas HAs with monobasic cleavage sites (single Arg) from low pathogenic viruses are expressed as the HA0 form [25]. NY107 is regarded as a low pathogenic virus, and as expected, was produced in the HA0 form (Figure S2). However, subsequent digestion with thrombin protease to remove the His-tag resulted in cleavage to a profile on SDS-PAGE comparable to that of an HA1/HA2 form (Figure S2).

A comparison of the NY107 cleavage site with the consensus cleavage pattern in the MEROPS database (http://merops.sanger.ac.uk) suggests it to be a possible thrombin cleavage site.

Based on their molecular phylogenies, HAs are divided into two groups and five clades: group 1 includes H8, H9, and H12; H1, H2, H5, and H6; H11, H13 and H16; group 2 includes H3, H4, and H14; H7, H10 and H15 [26]. Among all available HA structures, we selected ten representative HAs from both avian and human subtypes for structural analysis. As expected, NY107 HA is structurally very similar to the Avian-H7 in all comparisons and closely related to H3, the other group 2 members used in the analyses (Tables S1 and S2).

The receptor binding site

The RBS is at the membrane distal end of each HA monomer and its specificity for sialic acid and the nature of its linkage to a vicinal galactose residue is a major determinant of host range-restriction. The consensus RBS for all current HAs is composed of three major structural elements: a 190-helix (residues 188–194), a 220-loop (residues 221–228), and a 130-loop (residues 134–138). In addition, highly conserved residues (Tyr98, Thr153, His183, and Tyr195) form the base of the pocket.

Although the NY107 RBS is similar to other subtypes (H1, H2, H3, H5, and H9), a previously observed specific feature of H7 HAs, is also observed in the NY107 150-loop region: two residues inserted at position 158 result in this loop protruding more than 6 Å towards the binding site compared to other subtype HAs (Figure 1B and Table S2) [27]. More interestingly, the eight amino acid deletion, only found in the North American lineage H7s, from position 221 to 228 (Figure S1), resulted in a complete loss of the 220-loop (Figure 1B). Sequence alignment shows that Arg220 and Arg229 are conserved in all influenza A HA subtypes (Figure S1), but structural alignment of NY107 HA shows Arg220 occupying the Gly228 position, and the much shorter loop turns at residue Pro217 (Figure 1C). The Cα distance between NY107 Arg220 and its homolog in the Avian-H7 structure (PDB: 1TI8) [27] is 5.8 Å, and they point in opposite directions (Figure 1C). The side chain direction of Av-H7 Arg220 is almost parallel with the beta sheet after Arg229, whereas the NY107 Arg220 points downward to the binding pocket. The Cα position of Arg229 in both H7 structures remains the same, except the side chain in the NY107 swings away by about 5.9 Å (Figure 1C) and could help to stabilize this region by forming a hydrogen bond to the mainchain carbonyl of Gly210 in the neighboring monomer. In the absence of the 220-loop in NY107 HA, upon glycan binding the long side chain of Arg220 compensates for its loss and is displaced 4 Å upward to form hydrogen bonds with receptor analogs inside the binding pocket (Figure 1D).

Effect of loop truncation on the receptor binding specificity of NY107

Previously, mutations in the HA receptor binding domains of H1N1 (Glu190Asp/Gly225Asp) and H2N2/H3N2 (Glu226Leu and Gly228Ser) subtypes were responsible for adaptation of these viruses to pandemic strains [24,28,29,30]. Due to missing residues 221–228 in the NY107 HA RBS, neither mechanism for adaptation is possible. Thus, in order to look more closely at the role of the missing loop and its effect on receptor specificity, we first subjected the recombinant HA (recHA) to glycan microarray analyses and compared it to a reverse genetics-derived NY107 virus, and a co-circulating Eurasian virus and recHA, A/
Table 1. Data collection and refinement statistics.

| Data collection | NY107 | NY107+3 SLN | NY107+6 SLN | NY107+6 LSTb |
|-----------------|-------|------------|------------|-------------|
| **Refinement** |       |            |            |             |
| Resolution (Å)  | 50-2.6 (2.67-2.60) | 50-3.0 (3.08-3.00) | 50-2.6 (2.67-2.60) |             |
| No. of reflections (total) | 57285 | 51770 | 33421 | 53603 |
| No. of reflections (test) | 3053 | 2769 | 1779 | 2842 |
| Rmerge/Rfree | 21.7/25.6 | 21.4/26.4 | 20.5/26.0 | 20.4/24.7 |
| No. of atoms | 11795 | 11878 | 11648 | 12108 |
| r.m.s.d.- bond length (Å) | 0.006 | 0.006 | 0.008 | 0.006 |
| r.m.s.d.- bond angle (°) | 0.905 | 0.974 | 1.085 | 0.859 |
| MolProbity scores |       |            |            |             |
| Favored (%) | 96.9 | 96.5 | 94.3 | 97.1 |
| Outliers (%) | 0.1 (1/1434) | 0.0 (0/1429) | 0.1 (2/1433) | 0.1 (2/1433) |

*Numbers in parentheses refer to the highest resolution shell.

Reference [51].

*doi:10.1371/journal.ppat.1001081.t001

Glycan microarray analysis of recombinant NY107 (Figure 2A and Table 2) revealed a highly restricted binding profile with strong binding to only α2-3 sulfated (4–8), α2-3 branched (9–11) and mixed α2-3/α2-6 branched sialosides (60–64) as well as to the linear sialyl di-and tri-lactosamines (22, 24). Weak binding was also observed (above background) to other α2-3 glycans on the array. The recombinant NY107 also revealed a strict glycans binding preference to only one α2-6 glycan, the 60–64). In addition, sequence analysis of the NY107-220ins HA revealed the presence of quasispecies in the second position of the inserted loop, PQ/V/KVNGQSG, suggesting that re-introduction of the loop alone is not tolerated and does not create an avian-type binding profile. Thus other amino acid substitutions in the HA might have co-evolved with the deletion of the 220 loop to help stabilize the RBS/HA to maintain functionality.

When viruses containing this 220-loop deletion emerged in North America in the mid 90’s, four additional amino acid substitutions, Gly114Arg, Asp191Gly, Gly186Glu and Gly205Arg, in the HA1 as well as an Asp193Asn in the HA2 chain were also introduced to most of the circulating isolates. Of these, Gly186Glu and Gly205Arg in the HA1 are close to the RBS, at the monomer interface, and could potentially modulate its structure and/or function. NY107 viruses with a restored consensus 220-loop and a single Glu186Gly (NY107-ins-186) or Arg205Gly (NY107-ins-205) substitution as well as the Glu186Gly/Arg205Gly double substitution (NY107-ins-186/205) were derived by reverse genetics and evaluated. Glycan microarray analysis for the three resulting viruses revealed similar glycan binding profiles with increased binding to α2-3 sialosides, including mixed α2-3/α2-6 branched sialosides (60–64), α2-3 Neu5Gc (66–70), but limited binding to the α2,6 sialosides (Figures 3B, 3C, 3D), resulting in a binding profile virtually identical to that of the NL219 virus and other avian influenza viruses (Figure 2D) [30]. Sequence analysis of the three reverse genetics derived viruses revealed no mutations/quasispecies in the HA1 of either the NY107-ins-186 or the NY107-ins-186/205 virus stocks, indicative of replication fitness. For the NY107-ins-186 virus however, a Glu186Gly substitution emerged in the HA after only two passages in eggs following recovery from DNA transfection, indicating the importance of the co-variant position 186 with respect to HA functionality/glycan specificity. Altogether, the data indicates that the H7 subtype avian influenza viruses that were circulating in...
aquatic birds and poultry in North America before 1996 exhibited a classic avian α2-3 sialic acid binding preference. In order for the 220-loop deletion to be tolerated, concurrent Gly186Glu and Gly205Arg substitutions in the vicinity of RBS of HA emerged to achieve a restricted α2-3 binding profile and only a moderate/limited increase in binding to branched di-sialyl α2-6 biantennary structures (δ46–48) as well the α2,6 internal sialoside, LSTb (δ58).

NY107 avian receptor complex

To understand from a structural perspective how NY107 interacts with host receptors, we solved the structure of NY107 in complex with an avian and two human receptor analogs. For the avian receptor analog, 3'SLN, the electron density maps revealed well-ordered features for the Sia-1, Gal-2, and GlcNAc-3 in the NY107 HA complex structure (Figure 4A). Structural comparison of NY107 HA binding to other, H1, H2, H3, H5, and H9 subtypes (Figure S2A) revealed that 3'SLN binding to NY107 resembled binding of the other published HAs. Indeed, the terminal Sia-1 moiety is positioned almost identically in all structures, and forms the majority of hydrogen bonds and contacts with residues in the RBS (Figure 4A and Table S3).

Figure 1. NY107 HA monomer and comparison of its RBS to other HA structures. (A) One monomer is shown with the HA1 chain colored in green and the HA2 chain in cyan. The location of the receptor binding site and the HA1/HA2 cleavage site are circled. (B) The superposition of receptor binding domains of NY107 (green), Av-H7 (marine), 1918-Hu-H1 (magenta), Hu-H5 (yellow), Hu-H3 (orange), and Sw-H9 (grey). The proximity of Arg220 and Gln226 are highlighted. Three structural elements comprising this binding site are labeled. The two major differences are the extended 150-loop and the deletion of 220-loop of NY107. (C) Overlap of NY107 (green) and Av-H7 (marine) (PDB: 1TI8) illustrates the compensatory effect of R220 bringing it close to the position occupied by G228 in the avian HA. (D) Overlap of the NY107 (green), NY107-3'SLN (orange), NY107-6'SLN (red), and NY107-LSTb (magenta) structures. All the figures were generated and rendered with the use of MacPyMOL [56].

doi:10.1371/journal.ppat.1001081.g001
Published avian HA structures with an intact 220-loop form very close interactions with Gal-2 of SLN via residue Gln226 which is important in receptor specificity and host adaptation. For example, in the avian H7/3′SLN HA structure it interacts with Gal-2 O4 [31]. In the NY107 HA structure, although Gln226 is absent and no other residue occupies the same space as Gln226 (Figure 1B), Arg220 does forms a hydrogen bond between Arg220 NH2 and Gal-2 O4 (Figure 4A). Interestingly, although there was interpretable density for the GlcNAc-3 (Figure 4A and Figure S4B), no hydrogen bonding was apparent between the HA and the GlcNAc-3, which is consistent with other reported structures [32]. Thus, for binding to avian receptors, the trans conformation of α2-3 linkages is essential and perhaps only the first two saccharides are required. Indeed, due to the absence of 220-loop in the NY107 HA structure, the “aperture” of the RBS formed by 220-loop and 130-loop in regular HAs is increased by ~10 Å, so that the branched, internal, and perhaps more complicated glycans might be accommodated more efficiently.

**NY107 human receptor complexes**

In the NY107/6′SLN complex, only Sia-1 and Gal-2 are ordered (Figure 4B). The Sia-1 remains in the same position as previously analyzed glycan/HA complexes from H1, H2, H3, H5, and H9 (Figure S3B), whereas the Av-H7 complex structure with Sialyllacto-N-tetraose c (LSTc) did not reveal any density for the Sia-1 in the receptor binding site [31]. The Gal-2 position varies significantly among different subtypes. Compared to the human-adapted H1 HA [32], Gal-2 in the NY107 HA is 3 Å higher, and thus is further from the protein (Figure S3B). In NY107, the Gal-2 only forms an intramolecular, saccharide-saccharide interaction with Sia-1. The poor electron density map and fewer interactions with protein residues suggest that the cis conformation of α2-6
linkages in 6'SLN trisaccharides show a reduced binding affinity with NY107.

Glycan array results with NY107 revealed a strong binding signal for the internal 2-6 sialoside, LSTb. To further investigate this interaction, we solved the structure of the NY107/LSTb complex. The final model contained Sia-1, NAG-2, Gal-3, and Gal-5 in the RBS. Although glycan microarray data indicated NY107 to have a specific affinity for LSTb, few interactions were apparent from the crystal structure. Sia-1 still forms multiple hydrogen bonds with residues in the RBS (Table S3 & Figure 4C). The branched Gal-5 interacts with Ser137, to help stabilize the hydrogen bonds with residues in the RBS (Table S3 & Figure 4C).

Discussion

Human infections by avian influenza viruses, including H7 subtypes, continue to pose a major public health threat. Although the species barrier prevents avian influenza viruses from widespread infection of the human population, the molecular determinants of efficient interspecies transmission and pathogenicity are still poorly understood. The viral coat protein HA however, is perhaps a critical molecule since previous pandemic viruses modified their receptor specificity and overcame the interspecies barrier to spread in the human population. Although HA structures alone and in complex with receptor analogs provide considerable insight into receptor binding, it is clear that HAs from different species and subtypes have significant structural variation. Indeed, low-pathogenic H7N2 avian influenza viruses with an 8 amino acid deletion within its RBS started to circulate in live-bird markets in the northeastern United States in 1996. Despite what one would consider a debilitating mutation, these viruses have been reported as the predominant isolate [33]. Whether such a deletion contributed to their evolutionary success and how are important questions, especially in light of NY107’s ability to produce respiratory illness in humans [16], as well as its reported increased affinity for human-type receptors and ability for contact transmission in ferrets [21]. To try to help answer these questions, we have analyzed the molecular structures of NY107 and its complexes with receptor analogs to explain receptor specificity at the molecular level.

The crystal structures of NY107 and its complexes with both avian and human receptor analogs describe a mechanism as to how an influenza virus might adapt by dramatically altering its RBS, and still be functional. Arg220 of the HA1 chain of NY107 compensates for the loss of the 220-loop, by forming hydrogen bonds with Gal-2 from the avian analog (binding was not observed in either of the structures complexes with the human analogs). However, in the LSTb complex, branched Gal-5 forms extra interactions with the 130-loop, thus improving the binding preference for this particular glycan. Consistent with the structural evidence, glycan microarray analyses of NY107 revealed a strong binding preference for the branched 2-6 sialoside, LSTb. Except for the absence of the 220-loop, other key residues within the RBS are conserved in NY107 and thus, direct interactions with sialic acid are maintained.

The 220-loop is recognized as one of the three crucial structural elements in the RBS. Aside from the North American lineage H7N2 viruses, which have been circulating with a deletion (221–228) in this loop, there has been one other report describing a seven amino acid deletion (224–230) in a laboratory generated H3N2 escape mutant which was reported to have a slightly

Table 2. Comparison of the sialoside receptor specificity of the HAs from H7 influenza viruses.

| Glycan Group          | Glycan Group | NY107 RecHA | NY107 Virus | NY107-ins E186G Virus | NY107-ins R205G Virus | NY107-ins E186G/R205G Virus | NY107-ins E186G/NL219 RecHA | NY107-ins E186G/NL219 Virus |
|-----------------------|--------------|-------------|-------------|-----------------------|-----------------------|-----------------------------|-----------------------------|----------------------------|
| α2-3                  | Sulfated     | +++         | +++         | +++                   | +++                   | +++                         | +++                         | +++                        |
| Branched              | 9–11         | +++         | +           | +++                   | +++                   | +++                         | +++                         | +++                        |
| Linear                | 12–27        | +           | +++         | +++                   | +++                   | +++                         | +++                         | +++                        |
| Fucosylated           | 28–34        | –           | +++         | +++                   | +++                   | +++                         | +++                         | +++                        |
| α2-6                  | Sulfated     | 41          | –           | –                     | –                     | –                           | –                           | –                          |
| Branched mono-sialyl  | 42–45, 49    | –           | –           | –                     | –                     | –                           | –                           | –                          |
| Branched di-sialyl    | 46–48        | –           | +++         | –                     | –                     | –                           | –                           | –                          |
| Linear                | 50–56        | –           | –           | –                     | –                     | –                           | –                           | –                          |
| Internal              | 58–59        | +++         | +++         | –                     | –                     | –                           | –                           | –                          |
| Other                 | Sialic acid  | 1–2         | +++         | +                     | –                     | –                           | –                           | –                          |
| α2-3/α2-6 Branched    | 60–64        | –           | –           | +++                   | +++                   | +++                         | +++                         | +++                        |
| Neu5Gc                | 65–72        | –           | +++         | +++                   | +++                   | +++                         | +++                         | +++                        |

*Members of each group are identified according to the graph number used in the microarray data in Figures 2 and 3 and correspond to numbers in the complete glycan list (Table S4).

*Binding of samples to glycan subclasses are qualitatively estimated based on relative strength of the signal for the data shown in Figures 2 and 3: strong (+++), weak (+), absent (−).

*N-glycolyneuraminic acid.
doi:10.1371/journal.ppat.1001081.t002
increased affinity for α2-3-linked glycans by hemagglutination assay [34]. Meanwhile, the equivalent region in the hemagglutinin-esterase-fusion (HEF) protein of influenza C virus reveals a rearrangement resulting in a truncated 260-loop in its RBS (Figure S5) [35]. However, without structural data with appropriate receptor analogs, it is not possible to compare the role of these loop variants in receptor binding to the H7 HA structure described here.

When compared to NL219, another co-circulating H7 avian virus HA (Figure 2C and D), overall binding to α2-3-linked glycans was markedly reduced, while increased binding to α2-6-linked receptors was only marginal. However, these results focus attention on only 2 sub-classes of human-type receptors that may be important for infection (and transmission in ferrets). The NY107 virus interaction with biantennary glycans (Figure 2B), although weak (not seen in Figure 2A with recHA), is a possible route for virus entry as biantennary structures are common on tissues, i.e. glycan profiling data from human lung tissue on the Consortium for Functional Glycomics (CFG) web site. In addition, the internal sialoside, LSTb, was observed in both virus and recHA microarray data, suggesting this type of glycan has good affinity for this HA. The significance of this is unknown since LSTb has only been described in human milk [36].

Interestingly, NY107 and NL219 virus receptor binding and specificity has been addressed previously using glycan microarray analysis that reported a significantly increased preference for α2-6 and decreased preference for α2-3-linked sialosides [22]. In addition, the same viruses were also included in a recent study from Gambaryan et al. using a competitive solid-phase binding assay [23]. Our findings confirm and extend the receptor binding specificity reported by these authors in that they reported both viruses binding to sulfated sialylglycans with a lactosamine (Galβ1-4GlcNAc core and reported only a moderate binding affinity for α2-6-sialyllactosamine, the human-type receptor analog used in their assay.

The 220-loop is an integral feature of the receptor binding site, and thus one would predict that such a deletion might have compromised this strain to be deleted from the population of circulating viruses. However, this was not the case [33] and its existence appears to be in part due to the additional mutations at
positions 186 and 205. Restoration of the loop with either or both residues mutated back to the pre-1994 consensus sequence resulted in a classic avian influenza virus binding profile. The emergence of the Glu186Gly mutation in the HA of the NY107-ins-205 mutant after only two passages of the rescued virus in eggs, also indicates the importance of these positions for HA functionality/glycan specificity. Analysis of the structural data reveals that positions 186 and 205 are on opposite sides of a monomer but are both close to the 220-loop deletion region in the trimeric form. The Glu at position 186 is close to Arg220 and may interact with Arg220 when binding avian receptors. Position 205 in the neighboring monomer may be important in trimer stability and maintaining RBS functionality. If one models the pre-1996 220-loop restored into the NY107 structure, Arg205, Glu186 and the loop all clash, thus explaining the Glu186Gly mutation that emerged in the NY107-ins-205 virus HA after limited egg passage.

The NY107 RBS with its more restricted α2-3 glycan binding preference and weak/moderate increase in α2-6 binding may have given the virus a selective advantage to be maintained in poultry at live bird markets and supplying farms. Certain terrestrial birds, such as quails and chickens, have recently been shown to present both human and avian types of receptors in the trachea and intestine [37,38,39]. Although it is not known what specific glycans are presented in these animals, it is conceivable that a virus with mixed specificity might have a distinct advantage over avian viruses that have specific avian receptor requirements, particularly in bird markets where multiple species coalesce. Previous results with H7N2, H9N2 and H5N1 viruses all highlight the fact that an increase in α2-6-binding preference is not sufficient for efficient transmission of avian influenza viruses to humans [22,40,41]. Although it remains to be seen whether prolonged circulation of viruses in terrestrial birds, such as domestic chickens, can provide a possible route for viruses to adapt for efficient human infection [11], continued surveillance of influenza viruses from avian and other animal reservoirs is urgently needed to define their zoonotic potential.

Materials and Methods

Cloning

Based on H3 numbering [42], cDNA corresponding to residues 11–329 (HA1) and 1–176 (HA2) of the ectodomain of the hemagglutinin (HA) from A/New York/107/2003 (H7N2; Genbank:ACC55270) and A/Netherlands/219/2003 (H7N7; Genebank: AAR02640) was cloned into the baculovirus transfer vector, pAcGP67-A (BD Biosciences), incorporating a C-terminal thrombin cleavage site, a “foldon” sequence [43] and a His-tag at the extreme C-terminus of the construct to enable protein purification [23,44]. Transfection and virus amplification were carried out according to the baculovirus expression system manual (BD Biosciences Pharmingen).
Protein expression and purification

Soluble NY107 was recovered from the cell supernatant by metal affinity chromatography using Ni-NTA resin (Qiagen Inc.). Fractions containing NY107 were pooled and dialyzed against 10 mM Tris-SCN, 50 mM NaCl, pH 8.0, then subjected to ion-exchange chromatography (IEX) using a Mono-Q HR 10/10 column (GE Healthcare). IEX purified NY107 was subjected to thrombin digest (5 units/mg protein; overnight at 4°C) and purified by gel filtration chromatography using a Superdex-200 16/60 column (GE Healthcare) and 50 mM Tris-SCN, 100 mM NaCl, pH 8.0 as running buffer. Protein eluting as a trimer was buffer exchanged into 10 mM Tris-SCN, 50 mM NaCl, pH 8.0 and concentrated to 14.5 mg/ml for crystallization trials. At this stage, the protein sample still contained the additional plasmid-encoded residues at both the N (ADPG) and C terminus (SGRLVPR).

Crystallization, ligand soaking and data collection

Initial crystallization trials were set up using a Topaz Free Interface Diffusion (FID) Crystallizer system (Fluidigm Corporation, San Francisco, CA). Crystals were observed in several conditions containing PEG 3350 or PEG 4000. Following optimization, diffraction quality crystals for NY107 were obtained at room temperature using a modified method for microbat under oil [45], by mixing the protein with reservoir solution containing 20% PEG 3350, 0.2 M magnesium chloride at pH 7.2. For receptor analog complexes, crystals were soaked for 3 hours in the crystallization buffer containing 10 mM 3SLN or 6SLN (V-labs Inc., Covington, LA), or overnight in 10mM LSTb (Sigma, St. Louis, MO). All crystals were flash-cooled at 100K using 20% glycerol as the cryo-protectant. Datasets were collected at Advanced Photon Source (APS) beamlines 22 ID and BM at 100K. Data were processed with the DENZO-SACLEPACK suite [46]. Statistics for data collection are presented in Table 1.

Structure determination and refinement

The structure of NY107 was determined by molecular replacement with Phaser [47] using the structure of the avian H7 (Av-H7) from A/turkey/Italy/2002, pdb:1TIB (HA1, 78% identity; HA2, 90% identity) as the searching model. One HA trimer occupies the asymmetric unit with an estimated solvent content of 58% based on a Matthews’ coefficient (Vm) of 2.9 Å³/ Da. Rigid body refinement of the trimer led to an overall R/Rfree of 28.6%/37.4%. The model was then “mutated” to the correct sequence and rebuilt by Coot [48], then the protein structures were refined with REFMAC [49] using TLS refinement [50]. The three complex structures were refined and evaluated using MolProbity [51]. The three complex structures were refined and evaluated using the same strategy. All statistics for data processing and refinement are presented in Table 1. Electron density maps (2Fo-Fc) were generated in Refmac [49] while simulated annealing omit maps were generated by sa-omit-map, a part of the Crystallography and NMR System (CNS) software [32].

Virus generation

Wild type and mutant viruses of NY107 (H7N2) and A/Netherlands/219/2003 (H7N7) were generated from plasmids by a reverse genetics approach [53]. To generate viruses with amino acid insertion or substitution in the HA, mutations were introduced into plasmid DNA with an overlap extension PCR approach [54]. Viruses derived by plasmid transfection of HK293 cells were propagated in eggs. The genomes of resulting virus stocks were sequenced to detect the emergence of possible variants during amplification.

Glycan binding analyses

Glycan microarray printing and recHA analyses have been described previously [24,30,44,55] (see Table 2 for glycans used for analyses in these experiments). Virus were analyzed on the microarray as described previously [30].

PDB accession codes

The atomic coordinates and structure factors of NY107 are available from the RCSB PDB under accession codes 3M5G for the unliganded NY107, 3M5H for the NY107 with 3’SLN and 3M5I and 3M5J for NY107 with 6’SLN and LSTb, respectively.

Accession/ID numbers for genes/proteins used in this work

A/New York/107/03 (H7N2), Genbank: ACC55270; A/Netherlands/219/03 (H7N7), Genbank: AAR26040; A/Hong Kong/1-96/68 (H3N2), 2HMG; A/Duck/Ukraine/1/63 (H3N8), PDB: 1MQL; A/South Carolina/1/18 (H1N1), PDB: 1RD8; A/Puerto Rico/8/34 (H1N1), PDB: 1RU7; A/Swine/Iowa/15/30 (H1N1), PDB: 1RU7; A/Singapore/1/1957 (H2N2), PDB: 2WRC; A/Viet Nam/1203/04 (H5N1), PDB: 2FK0; A/Duck/Singapore/3/97 (H5N3), PDB: 1JSM; A/Swine/Hong Kong/9/98 (H9N2), PDB: 1JSF; A/Turkey/Italy/8000/02 (H7N3), PDB: 1TB8; C/Johannesburg/1/66, 1FLC.

Supporting Information

Figure S1 Sequence alignment of selected structurally available HAs. Human H3 (PDB: 2HMG), Avian H3 (PDB: 1MQL), 1918-Human H1 (PDB: 1RD8), 1934-Human H1 (PDB: 1RU7), Swine H1 (PDB: 1RU7), 1957-Hu-H2 (PDB: 2WRC), Human H5 (PDB: 2FK0), Avian H5 (PDB: [JSM], Swine H9 (PDB: 1JSF), and Avian H7 (PDB: 1TB8) were used in the alignments. The fusion domain of HAI is highlighted in magenta, the vestigial esterase domain is highlighted in blue, the receptor binding domain is highlighted in blue, and the fusion domain of HA2 is highlighted in red. Residue numbering is based on the H3 HA sequence. Found at: doi:10.1371/journal.ppat.1001081.s001 (2.84 MB TIF)

Figure S2 Expression and purification of NY107. SDS-PAGE reveals that NY107 was expressed as the HA0 form with a mass approximately 60kDa (middle lane). Thrombin cleavage resulted in a reduced band size to HA1/HA2 profile (right lane) with possible multiple glycoforms for the HA2 clearly present. Found at: doi:10.1371/journal.ppat.1001081.s002 (0.23 MB TIF)

Figure S3 Comparison of glycan binding to NY107 with other HAs. A. Overlap of 2-3 ligands binding in the receptor binding site of NY-H7 (green), Av-H3 (orange), 1930-Hu-H2 (cyan), Av-H5 (yellow), and Sw-H9 (grey). B. Overlap of 2-6 linkage ligands binding in the receptor binding site of NY-H7 (green), Av-H3 (orange), 1930-Hu-H1 (magenta), 1957-Hu-H2 (cyan), Av-H5 (yellow), and Sw-H9 (grey). Found at: doi:10.1371/journal.ppat.1001081.s003 (2.55 MB TIF)

Figure S4 Simulated annealing omit maps of the receptor binding site (contoured at 1σ). A. NY107 (blue), B. NY107-3’SLN (orange), C. NY107-6’SLN (red), and D. NY107-LSTb (magenta). The protein model is shown in cartoon, and the residues involved in the binding to receptor analogs were shown in sticks. Maps were generated using version 1.2 of the Crystallography and NMR System (CNS) software. Found at: doi:10.1371/journal.ppat.1001081.s004 (1.93 MB TIF)
Figure S5  Comparison of NY107 RBS to HEF. Overlap of RBS from NY107 (green), Av-H7 (marine) and HEF (magenta). Found at: doi:10.1371/journal.ppat.1001081.s005 (1.12 MB TIF)

Table S1  Comparison of r.m.s.d. (Å) for different HA domains. For analyzing differences in the overall structure, r.m.s.d. values were calculated between monomers or domains of different HA’s, after the Cx atoms of the HA2 domains were superposed by sequence and structural alignment onto the equivalent domains of NY107.

Table S2  Comparison of r.m.s.d. (Å) for individual domains. Each domain was superimposed separately to determine how the individual NY107 domains compared to equivalent domains in the other structures.

Table S3  Molecular interactions between NY107 and receptor analogs. The hydrogen bond cutoff is 3.8 Å for the listing interactions.

Table S4  Glycan array differences between NY107, the fully restored NY107-ins, and NL219 (virus and rHA). The color coding in the left hand column reflects the same coloring scheme for the data shown in Figures 2 and 3 Strong (+++), weak (+).

Acknowledgments

The authors would like to thank the staff of SER-CAT sector 22 for their help in data collection. We also thank WHO Global Influenza Surveillance Network for providing NY107 and NL219 viruses from which the reverse genetics viruses were generated. Glycan microarray data presented here will be made available on-line through the CFG web site upon publication (www.functionalglycomics.org). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry.

Author Contributions

Conceived and designed the experiments: HY LMC PJC ROD JS. Performed the experiments: HY LMC PJC JS. Analyzed the data: HY LMC PJC ROD JS. Wrote the paper: HY LMC PJC ROD JS.

References

1. Thompson WW, Shay DK, Weintraub E, Bramer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179–186.
2. Thompson WW, Shay DK, Weintraub E, Bramer L, Bridges CB, et al. (2004) Influenza-associated hospitalizations in the United States. JAMA 292: 1333–1340.
3. WHO (1980) A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull, WHO 58: 385–391.
4. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, et al. (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79: 2014–2022.
5. Scholtissek C, Rohde W, Von Hoyningen V, Rott R (1978) On the origin of the influenza A virus in swine in Germany. J. Influenza 15: 167–179.
6. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, et al. (2006) Avian flu: a clue to pandemic warning? Nature 444: 435–436.
7. Matrosovich MN, Gambaryan AS, Tsenev Bog, Pokares YE, Vannikova VS, et al. (1997) Avian influenza A viruses differ from human viruses by recognition of sialyloligosaccharides and gangliosides and by a higher conservation of the HA receptor-binding site. Virology 233: 224–234.
8. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lam WL. (1997) A pandemic warning? Nature 389: 534.
9. Tambeuenberg JK, Mooren DM, Fauci AS (2007) The next influenza pandemic: can it be predicted? JAMA 297: 2025–2027.
10. Webster RG, Geraedts JP, Petersson K, Skerking OR, (2004) Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 101: 1536–1531.
11. Kurtz J, Maxwell RJ, Banks J (1996) Avian influenza virus isolated from a domestic turkey. J Infect Dis 173: 1302–1304.
12. Webster RG, Geraci J, Petursson G, Skirnisson K (1981) Conjunctivitis in human beings caused by influenza A virus of seals. N Engl J Med 304: 911–915.
13. Kurtz J, Maxwell RJ, Banks J (1996) Avian influenza virus isolated from a domestic turkey. J Infect Dis 173: 1302–1304.
14. Koopmans M, Uilenkamp B, Conyn M, Natrop G, van der Nat H, et al. (2004) Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363: 597–599.
15. Fouchier RA, Schneeberger PM, Roumen RMF, Broekman JM, Kemink SA, et al. (2004) Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 101: 1536–1531.
16. CDC (2004) Update: influenza activity—United States and worldwide, 2003–04 season, and composition of the 2004–05 MMWR Morb Mortal Wkly Rep. Centers for Disease Control pp 542–547.
17. Hirst M, Astell CR, Griffith M, Coughlin SM, Moks A, et al. (2004) Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis 10: 2192–2195.
18. Tweed SA, Skowronski DM, David ST, Larder AP, Petric M, et al. (2004) Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis 10: 2196–2199.
19. Editorial Team (2007) Avian influenza A/H7N2 outbreak in the United Kingdom. Euro Surveill 12: 2.
20. Suarez DL, Garcia M, Latimer J, Senne D, Perdue M (1999) Phylogenetic analysis of H7 avian influenza viruses isolated from the live bird markets of the Northeast United States. J Virol 73: 3567–3573.
21. Beber JA, Lu X, Maines TR, Smith C, Li Y, et al. (2007) Pathogenesis of avian influenza H7N7 virus infection in mice and ferrets: enhanced virulence of Eurasian H7N7 viruses isolated from humans. J Virol 81: 11139–11147.
22. Beber JA, Blatz O, Chen LM, Pappas C, Maines TR, et al. (2008) Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility. Proc Natl Acad Sci U S A 105: 7535–7543.
23. Gambaryan AS, Tuzikov AB, Pazynina GV, Devesha JA, Bovin NV, et al. (2008) s-sialofetidin Lewis X is the common receptor determinant recognized by H5, H6, H7 and H9 influenza viruses of terrestrial poultry. Virology J 5: 85.
24. Stevens J, Blatz O, Glaser I, Taubenberger JK, Palese P, et al. (2006) Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol 355: 1143–1155.
25. Stevens J, Corper AL, Badier CF, Taubenberger JK, Palese P, et al. (2004) Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303: 1866–1870.
26. Russell RJ, Berry PS, Stevens DJ, Steinhauser DA, Martin SR, et al. (2008) Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A 105: 17736–17741.
27. Russell RJ, Gamblin SJ, Haire LF, Stevens DJ, Xiao B, et al. (2004) H1 and H7 influenza haemagglutinin truncated viral surface antigens extend a structural classification of haemagglutinin subtypes. Virology 325: 287–296.
28. Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov A, et al. (2000) Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol 74: 8502–8512.
29. Nobusawa E, Ishihara H, Morishita T, Sato K, Nakajima K (2000) Change in receptor-binding specificity of recent human influenza A viruses (H5N1): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology 278: 507–596.
30. Stevens J, Blatz O, Chen LM, Donis RO, Paulson JC, et al. (2008) Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol 381: 1392–1394.
31. Russell RJ, Stevens DJ, Haire LF, Gamblin SJ, Skehel JJ (2006) Avian and human receptor binding by hemagglutinins of influenza A viruses. Glycobiology 16: 793–803.
32. Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, et al. (2004) The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303: 1838–1842.
33. Suarez DL, Stackman R, Senne DA (2003) Update on molecular epidemiology of H1, H5, and H7 influenza viruses in poultry in North America. Avian Dis 47: 883–897.
34. Daniels PS, Jeffries S, Yates P, Schild GC, Rogers GN, et al. (1987) The receptor-binding and membrane-fusion properties of influenza virus variants.
selected using anti-haemagglutinin monoclonal antibodies. EMBO J 6: 1459–1465.
35. Rosenthal PB, Zhang X, Formanowski F, Fitz W, Wong CH, et al. (1998) Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus. Nature 396: 92–96.
36. Weinstein J, de Souza-e-Silva U, Paulson JC (1982) Purification of a Gal beta 1 to 4GlcNAc alpha 2 to 6 sialyltransferase and a Gal beta 1 to 3/4GlcNAc alpha 2 to 3 sialyltransferase to homogeneity from rat liver. J Biol Chem 257: 13935–13944.
37. Gambaeryan A, Webster R, Matrosovich M (2002) Differences between influenza virus receptors on target cells of duck and chicken. Arch Virol 147: 1197–1208.
38. Watanabe M, Pfeifer DR (2006) Quail carry sialic acid receptors compatible with binding of avian and human influenza viruses. Virology 346: 278–296.
39. Guo CT, Takahashi N, Yagi H, Kato K, Takahashi T, et al. (2007) The quail and chicken intestine have sialyl-galactose sugar chains responsible for the binding of influenza A viruses to human type receptors. Glycobiology 17: 713–724.
40. Mains TR, Chen LM, Matsuoka Y, Chen H, Rowe T, et al. (2006) Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A 103: 12121–12126.
41. Watanabe M, Sorrell EM, Song H, Hossain MJ, Ramirez-Nieto G, et al. (2008) Replication and transmission of H9N2 influenza viruses in ferrets: evaluation of pandemic potential. PLoS One 3: e2929.
42. Wei W, Brunger AT, Skehel JI, Wiley DC (1990) Refinement of the influenza virus hemagglutinin by simulated annealing. J Mol Biol 212: 737–761.
43. Frank S, Kamerer RA, Mechling D, Schultheiss T, Landwehr R, et al. (2001) Stabilization of short collagen-like triple helices by protein engineering. J Mol Biol 310: 1081–1099.
44. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006) Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312: 404–410.
45. Chayen NE, Shaw-Steward PD, Blow DM (1992) Microbatch crystallization under oil – a new technique allowing many small volume crystallization experiments. J Cryst Growth 122: 176–180.
46. Otwinowski A, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods in Enzymology 276: 307–326.
47. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61: 450–464.
48. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126–2122.
49. CCP4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760–763.
50. Watanabe M, Isupov MN, Murshudov GN (2001) Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr 57: 122–133.
51. Lewis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, et al. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35: W375–383.
52. Brunger AT (2007) Version 1.2 of the Crystallography and NMR system. Nat Protoc 2: 2726–2733.
53. Hoffmann E, Webster RG (2000) Unidirectional RNA polymerase I-polymerase II transcription system for the generation of influenza A virus from eight plasmids. J Gen Virol 81: 2843–2847.
54. Higuchi R, Krummel B, Saiki RK (1988) A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res 16: 7351–7367.
55. Blixt O, Head S, Mondala T, Scanlan C, Hudfent ME, et al. (2004) Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A 101: 17033–17038.
56. DeLano WL (2002) The PyMol Molecular Graphics Systems. www.pymol.org.